Amgen Statistics
Total Valuation
Amgen has a market cap or net worth of $185.54 billion. The enterprise value is $230.69 billion.
| Market Cap | 185.54B |
| Enterprise Value | 230.69B |
Important Dates
The last earnings date was Tuesday, November 4, 2025, after market close.
| Earnings Date | Nov 4, 2025 |
| Ex-Dividend Date | Nov 21, 2025 |
Share Statistics
Amgen has 538.48 million shares outstanding. The number of shares has increased by 0.28% in one year.
| Current Share Class | 538.48M |
| Shares Outstanding | 538.48M |
| Shares Change (YoY) | +0.28% |
| Shares Change (QoQ) | +0.18% |
| Owned by Insiders (%) | 0.15% |
| Owned by Institutions (%) | 80.75% |
| Float | 537.12M |
Valuation Ratios
The trailing PE ratio is 26.64 and the forward PE ratio is 16.36. Amgen's PEG ratio is 3.29.
| PE Ratio | 26.64 |
| Forward PE | 16.36 |
| PS Ratio | 5.15 |
| Forward PS | 4.94 |
| PB Ratio | 19.29 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 16.08 |
| P/OCF Ratio | 14.14 |
| PEG Ratio | 3.29 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.00, with an EV/FCF ratio of 19.99.
| EV / Earnings | 32.93 |
| EV / Sales | 6.41 |
| EV / EBITDA | 14.00 |
| EV / EBIT | 20.67 |
| EV / FCF | 19.99 |
Financial Position
The company has a current ratio of 1.28, with a Debt / Equity ratio of 5.67.
| Current Ratio | 1.28 |
| Quick Ratio | 0.82 |
| Debt / Equity | 5.67 |
| Debt / EBITDA | 3.27 |
| Debt / FCF | 4.73 |
| Interest Coverage | 3.32 |
Financial Efficiency
Return on equity (ROE) is 81.71% and return on invested capital (ROIC) is 10.56%.
| Return on Equity (ROE) | 81.71% |
| Return on Assets (ROA) | 7.71% |
| Return on Invested Capital (ROIC) | 10.56% |
| Return on Capital Employed (ROCE) | 16.33% |
| Revenue Per Employee | $1.28M |
| Profits Per Employee | $250,179 |
| Employee Count | 28,000 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 1.57 |
Taxes
In the past 12 months, Amgen has paid $1.24 billion in taxes.
| Income Tax | 1.24B |
| Effective Tax Rate | 15.03% |
Stock Price Statistics
The stock price has increased by +17.20% in the last 52 weeks. The beta is 0.46, so Amgen's price volatility has been lower than the market average.
| Beta (5Y) | 0.46 |
| 52-Week Price Change | +17.20% |
| 50-Day Moving Average | 304.95 |
| 200-Day Moving Average | 295.39 |
| Relative Strength Index (RSI) | 70.84 |
| Average Volume (20 Days) | 3,086,552 |
Short Selling Information
The latest short interest is 13.43 million, so 2.49% of the outstanding shares have been sold short.
| Short Interest | 13.43M |
| Short Previous Month | 11.48M |
| Short % of Shares Out | 2.49% |
| Short % of Float | 2.50% |
| Short Ratio (days to cover) | 6.11 |
Income Statement
In the last 12 months, Amgen had revenue of $35.97 billion and earned $7.01 billion in profits. Earnings per share was $12.93.
| Revenue | 35.97B |
| Gross Profit | 25.20B |
| Operating Income | 11.16B |
| Pretax Income | 8.24B |
| Net Income | 7.01B |
| EBITDA | 16.48B |
| EBIT | 11.16B |
| Earnings Per Share (EPS) | $12.93 |
Balance Sheet
The company has $9.45 billion in cash and $54.59 billion in debt, giving a net cash position of -$45.14 billion or -$83.83 per share.
| Cash & Cash Equivalents | 9.45B |
| Total Debt | 54.59B |
| Net Cash | -45.14B |
| Net Cash Per Share | -$83.83 |
| Equity (Book Value) | 9.62B |
| Book Value Per Share | 17.86 |
| Working Capital | 6.09B |
Cash Flow
In the last 12 months, operating cash flow was $13.13 billion and capital expenditures -$1.59 billion, giving a free cash flow of $11.54 billion.
| Operating Cash Flow | 13.13B |
| Capital Expenditures | -1.59B |
| Free Cash Flow | 11.54B |
| FCF Per Share | $21.43 |
Margins
Gross margin is 70.05%, with operating and profit margins of 31.02% and 19.47%.
| Gross Margin | 70.05% |
| Operating Margin | 31.02% |
| Pretax Margin | 22.92% |
| Profit Margin | 19.47% |
| EBITDA Margin | 45.82% |
| EBIT Margin | 31.02% |
| FCF Margin | 32.08% |
Dividends & Yields
This stock pays an annual dividend of $9.52, which amounts to a dividend yield of 2.76%.
| Dividend Per Share | $9.52 |
| Dividend Yield | 2.76% |
| Dividend Growth (YoY) | 5.78% |
| Years of Dividend Growth | 15 |
| Payout Ratio | 73.61% |
| Buyback Yield | -0.28% |
| Shareholder Yield | 2.48% |
| Earnings Yield | 3.78% |
| FCF Yield | 6.22% |
Analyst Forecast
The average price target for Amgen is $313.31, which is -9.07% lower than the current price. The consensus rating is "Hold".
| Price Target | $313.31 |
| Price Target Difference | -9.07% |
| Analyst Consensus | Hold |
| Analyst Count | 14 |
| Revenue Growth Forecast (5Y) | 3.82% |
| EPS Growth Forecast (5Y) | 26.69% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on November 22, 1999. It was a forward split with a ratio of 2:1.
| Last Split Date | Nov 22, 1999 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Amgen has an Altman Z-Score of 1.69 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.69 |
| Piotroski F-Score | 7 |